Skip to content

Author

A. Xu-Vuillard

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Selective estrogen receptor degraders in premenopausal breast cancer: Biological activity and endpoint relevance in window of opportunity trials.

Selective estrogen receptor degraders (SERDs) have emerged as a key therapeutic class in hormone receptor-positive (HR+) breast cancer, combining estrogen receptor (ER) antagonism with direct receptor degradation. Despite this dual mechanism, pivotal trials of SERDs in premenopausal patients-across both metastatic and...

Ana-Maria Dudău, J. Zeghondy, G. Emile et al. · 0 citations
Review Open access Sep 2026

Randomised phase III trials of cancer prevention drugs: a systematic review and prediction of trial success

Background Pharmacological cancer risk reduction has received far less investment than therapeutic oncology and only a few agents have entered routine practice. Understanding the predictors of positive outcomes of previous trials and issues faced is critical to future developments. Methods This systematic review (PROSP...

A. Xu-Vuillard, B. Duso, B. Arun et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.